Impact of the UK COVID-19 pandemic on HbA1c testing and its implications
for diabetes diagnosis and management
Abstract
Our findings illustrate the widespread collateral impact of implementing
measures to mitigate the impact of COVID-19 in people with, or being
investigated for diabetes mellitus (DM). Ironically, failure to focus of
the wider implications for people with DM and other groups with
long-term conditions, may place them at increased risk of poor outcomes
from SARS-CoV-2 infection itself, irrespective of the implications for
their longer-term health prospects.
, 
